Counterpoint: Is there a need for supplemental XRT in intermediate-risk prostate cancer patients?

[1]  M. Cooperberg,et al.  Primary treatments for clinically localised prostate cancer: a comprehensive lifetime cost‐utility analysis , 2013, BJU international.

[2]  M. Zelefsky,et al.  Secondary cancers after intensity‐modulated radiotherapy, brachytherapy and radical prostatectomy for the treatment of prostate cancer: incidence and cause‐specific survival outcomes according to the initial treatment intervention , 2012, BJU international.

[3]  G. Gustafson,et al.  Brachytherapy provides comparable outcomes and improved cost-effectiveness in the treatment of low/intermediate prostate cancer. , 2012, Brachytherapy.

[4]  Charles A Enke,et al.  Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines. , 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

[5]  K. McConway,et al.  The results of real‐time brachytherapy for the management of low‐ and intermediate‐risk prostate cancer in patients with prostate volumes up to 100 mL , 2012, BJU international.

[6]  S. Lipsitz,et al.  Cost implications of the rapid adoption of newer technologies for treating prostate cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  P. Unger,et al.  Influence of pretreatment and treatment factors on intermediate to long-term outcome after prostate brachytherapy. , 2011, The Journal of urology.

[8]  R. Stock,et al.  Long‐term potency preservation following brachytherapy for prostate cancer , 2010, BJU international.

[9]  Wayne M Butler,et al.  Natural history of clinically staged low- and intermediate-risk prostate cancer treated with monotherapeutic permanent interstitial brachytherapy. , 2010, International journal of radiation oncology, biology, physics.

[10]  R. Stock,et al.  Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy. , 2009, International journal of radiation oncology, biology, physics.

[11]  M. Cooperberg,et al.  Health related quality of life in patients treated with multimodal therapy for prostate cancer. , 2008, The Journal of urology.

[12]  Kara Hamilton,et al.  Second primary cancer after radiotherapy for prostate cancer--a seer analysis of brachytherapy versus external beam radiotherapy. , 2008, International journal of radiation oncology, biology, physics.

[13]  Michael W Kattan,et al.  Customized dose prescription for permanent prostate brachytherapy: insights from a multicenter analysis of dosimetry outcomes. , 2007, International journal of radiation oncology, biology, physics.

[14]  R. Stock,et al.  Long-term urinary, sexual, and rectal morbidity in patients treated with iodine-125 prostate brachytherapy followed up for a minimum of 5 years. , 2007, Urology.

[15]  Barry S Rosenstein,et al.  Biologically effective dose values for prostate brachytherapy: effects on PSA failure and posttreatment biopsy results. , 2005, International journal of radiation oncology, biology, physics.

[16]  W. Cavanagh,et al.  Rectal fistulas after prostate brachytherapy. , 2005, International journal of radiation oncology, biology, physics.

[17]  Louis Potters,et al.  12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. , 2005, The Journal of urology.

[18]  R. Stock,et al.  Urinary morbidity and incontinence following transurethral resection of the prostate after brachytherapy. , 2005, The Journal of urology.

[19]  M. Sarosdy.  Urinary and rectal complications of contemporary permanent transperineal brachytherapy for prostate carcinoma with or without external beam radiation therapy , 2004, Cancer.

[20]  K. Wallner,et al.  Late rectal function after prostate brachytherapy. , 2003, International journal of radiation oncology, biology, physics.

[21]  K. Wallner,et al.  Long-term urinary quality of life after permanent prostate brachytherapy. , 2003, International journal of radiation oncology, biology, physics.

[22]  K. Wallner,et al.  Dysuria after permanent prostate brachytherapy. , 2003, International journal of radiation oncology, biology, physics.

[23]  W. Butler,et al.  Erectile function after permanent prostate brachytherapy. , 2002, International journal of radiation oncology, biology, physics.

[24]  C C Ling,et al.  High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. , 2001, The Journal of urology.

[25]  A. Renshaw,et al.  Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. , 1998, JAMA.

[26]  R. Stock,et al.  A dose-response study for I-125 prostate implants. , 1998, International journal of radiation oncology, biology, physics.

[27]  R. Stock,et al.  The effect of prognostic factors on therapeutic outcome following transperineal prostate brachytherapy. , 1997, Seminars in surgical oncology.

[28]  K. Wallner,et al.  Gleason score 7 prostate cancer treated with interstitial brachytherapy with or without supplemental external beam radiation and androgen deprivation therapy: is the primary pattern on needle biopsy prognostic? , 2013, Brachytherapy.

[29]  R. Stock,et al.  Factors influencing urinary symptoms 10 years after permanent prostate seed implantation. , 2012, The Journal of urology.

[30]  D. Ash,et al.  Outcomes following iodine-125 monotherapy for localized prostate cancer: the results of leeds 10-year single-center brachytherapy experience. , 2010, International journal of radiation oncology, biology, physics.

[31]  R. Stock,et al.  (125)I monotherapy using D90 implant doses of 180 Gy or greater. , 2008, International journal of radiation oncology, biology, physics.

[32]  Marco Zaider,et al.  Five-year outcome of intraoperative conformal permanent I-125 interstitial implantation for patients with clinically localized prostate cancer. , 2007, International journal of radiation oncology, biology, physics.

[33]  Robert W Galbreath,et al.  15-Year biochemical relapse free survival in clinical Stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience. , 2007, International journal of radiation oncology, biology, physics.